Sector Update: Health Care Stocks Struggle Tuesday
4:09PM ET 7/05/2022 MT NewswiresHealth care stocks continued to sputter this afternoon, with the NYSE Health Care Index sinking 0.8% and the SPDR Health Care Select Sector ETF (XLV) down...
Quotes Snapshot > OTLK
Outlook Therapeutics Inc OTLK:NASDAQ
Last Price$1.20NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/18/22
Today's Change-0.01(0.83%)
Bid (Size)$1.19 (11)
Ask (Size)$1.30 (7)
Day Low / High$1.16 - 1.26
Volume284.8 K
Read more news Recent News
Sector Update: Health Care Stocks Retreating in Tuesday Trade
1:44PM ET 7/05/2022 MT NewswiresHealth care stocks were mostly lower this afternoon, with the NYSE Health Care Index sinking 2.2% and the SPDR Health Care Select Sector ETF (XLV) down...
Outlook Therapeutics Makes Full Cash Pre-Payment of Convertible Promissory Note; Shares Rise Midday
12:29PM ET 7/05/2022 MT NewswiresOutlook Therapeutics (OTLK) said Tuesday that it made a full cash pre-payment of its unsecured convertible promissory note dated Nov. 4, 2020, and that all...
Outlook Therapeutics to Refile Biologics License Application With FDA for ONS-5010 by September; Shares Rise
9:47AM ET 6/14/2022 MT NewswiresOutlook Therapeutics (OTLK) said Tuesday it expects to re-submit the biologics license application for ONS-5010 to treat wet age-related macular...
View all Commentary and Analysis
Outlook Therapeutics: A One-Buck Lottery Ticket
2:27PM ET 6/09/2022 Seeking AlphaOutlook Therapeutics (OTLK) Investor Presentation - Slideshow
4:48PM ET 5/13/2022 Seeking AlphaOutlook Therapeutics: Likely FDA Approval, Possible Buyout
2:00PM ET 1/21/2022 Seeking AlphaWall Street Breakfast: The Week Ahead (Podcast)
7:21AM ET 10/10/2021 Seeking AlphaCompany Profile
Business DescriptionOutlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. View company web site for more details
| Address | 485 Route 1 South Iselin, New Jersey 08830 |
| Phone | +1.609.619.3990 |
| Number of Employees | 56 |
| Recent SEC Filing | 08/15/2022 3 |
| President, Chief Executive Officer & Director | C. Russell Trenary |
| Chief Operating Officer | Terry Dagnon |
| CFO, Secretary, Treasurer & Director | Lawrence A. Kenyon |
| Senior Vice President-Clinical Development | Jennifer M. Kissner |
Company Highlights
| Price Open | $1.21 |
| Previous Close | $1.21 |
| 52 Week Range | $0.68 - 2.87 |
| Market Capitalization | $271.4 M |
| Shares Outstanding | 226.1 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 12/28/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.32 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.1 M |
| Net Profit Margin | N/A |
| Return on Equity | -237.90% |
Analyst Ratings as of 02/14/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |